We have identified new malaria vaccine candidates through the combination of bioinformatics prediction of stable protein domains in the Plasmodium falciparum genome, chemical synthesis of polypeptides, in vitro biological functional assays, and association of an antigen-specific antibody response with protection against clinical malaria.
To our knowledge, this is the first time that mucosal vaccination has been demonstrated to be efficacious for directly preventing parasite transmission from vaccinated animals to mosquitoes, and the results may provide important insight into rational design of nonparenteral vaccines for use against human malaria.
However, there are many settings where knowlesi transmission to humans would be expected but is not found. A recent report on the Ra-glai population of southern central Vietnam is taken as an example to help explain why this may be so.
Here we present a new map of malaria risk for Kenya in 2009.
This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34.
No abstract available.
In an effort to broaden the immune response induced by the RTS,S/AS02A,vaccine, we have evaluated the immunogenicity of the RTS,S antigen when combined with MSP142 and with AMA1, antigens derived from the asexual blood stage.
Further work is required to ascertain whether ease of use and compliance may be important factors in the outcomes associated with malariachemoprophylaxis.
If a mosquito-transmitted brain tumor virus could be identified, development of a brain tumor vaccine might be possible.